CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02400463
NCT02400463Phase 2Completed
CompareCT.gov

Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

University of Michigan Rogel Cancer Center·interventional·Posted Mar 27, 2015·Updated Jan 25, 2021

In Brief

A Phase 2 clinical trial evaluating Ruxolitinib for Hemophagocytic Syndrome (HPS). Completed, enrolled 6 participants across 1 site.

Detailed Summary

This is a pilot study to determine the efficacy of Ruxolitinib in secondary hemophagocytic syndrome. The primary objective is to assess the efficacy of ruxolitinib 15 mg PO twice daily in patients with HPS. The primary endpoint is overall survival at two months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophagocytic Syndrome (HPS)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 27, 2015
Enrollment StartFeb 5, 2016
Primary CompletionOct 10, 2019
Study CompletionJan 7, 2020
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.3 years ago

Interventions

Ruxolitinibdrug